FSSAI: Initiates 3 Nestle India Infant Food Adjudication Cases

• The FSSAI has initiated three adjudication cases against Nestle India concerning alleged regulatory violations related to infant nutrition products.
• Two cases involve promotional claims for NAN Excella Pro Stage 1 and Lactogen Pro 1, which are alleged to violate the 2020 Infant Nutrition Regulations and the 1992 Infant Milk Substitutes Act.
• A third case addresses a confirmed biotin shortfall in a sample of Nestle India's follow-up infant formula, failing to meet prescribed nutritional standards.
• These actions highlight increased regulatory scrutiny over both marketing ethics and the nutritional composition of infant food products in India.
• The FSSAI's enforcement underscores a global trend of caution regarding ingredient-level claims that might suggest formula superiority to breastfeeding.

Legal and compliance teams within the infant nutrition sector, particularly in India, must urgently review their product marketing claims and formulation compliance, as FSSAI is demonstrating heightened scrutiny and enforcement actions under the IMS Act and the 2020 Infant Nutrition Regulations, setting a precedent for similar regulatory challenges.

The Food Safety and Standards Authority of India (FSSAI) has launched three distinct adjudication cases against Nestle India, signaling heightened regulatory scrutiny over the marketing and nutritional composition of infant food products. These actions stem from alleged non-compliance concerning two specific infant nutrition items, NAN Excella Pro Stage 1 and Lactogen Pro 1, as well as a separate finding related to a follow-up infant formula. The cases underscore a robust enforcement approach by the FSSAI, particularly under the stringent provisions of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020, and the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992.

The regulatory body's investigation into Nestle India's infant food portfolio has identified two primary areas of concern. Firstly, promotional claims made for NAN Excella Pro Stage 1 and Lactogen Pro 1 are under review for potentially violating advertising restrictions. Secondly, a follow-up infant formula manufactured by the company was found to contain a biotin shortfall, failing to meet prescribed nutritional standards. These developments highlight the FSSAI's commitment to ensuring that infant nutrition products adhere strictly to both marketing ethics and compositional requirements, reflecting a broader national policy emphasis on infant health and appropriate feeding practices.

A significant portion of the FSSAI's action targets specific promotional claims made by Nestle India for its infant nutrition products. For NAN Excella Pro Stage 1, the regulator flagged claims such as "5 HMOs" and "Whey Protein" that appeared on product packaging and in online promotional materials. Similarly, for Lactogen Pro 1, concerns were raised regarding a claim that described its "Whey Protein" as "easy to digest." The FSSAI asserts that these claims contravene Regulation 4(2) of the Food Safety and Standards (Foods for Infant Nutrition) Regulations, 2020.

This particular regulation is designed to restrict promotional claims and materials intended to boost the saleability of infant foods, reflecting a fundamental regulatory principle that marketing should not influence infant feeding choices away from breastfeeding or clinically appropriate nutrition. Furthermore, the FSSAI has invoked Section 3 of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992. This standalone statute explicitly prohibits the advertisement and promotion of infant milk substitutes, feeding bottles, and infant foods, having been enacted to curb aggressive marketing tactics by manufacturers. Nestle India has been asked to provide clarifications regarding these claims, indicating an opportunity for the company to formally respond before further proceedings.

Beyond marketing practices, a separate and independent adjudication case against Nestle India concerns a critical nutritional deficiency. A sample of a follow-up infant formula, produced by the company, was discovered to be sub-standard in its biotin content during a routine laboratory analysis. Biotin, a vital B-vitamin, is among the essential nutrients explicitly mandated under the 2020 Food Safety and Standards (Foods for Infant Nutrition) Regulations for follow-up formulas, which are intended for infants transitioning beyond exclusive milk feeding.

Following an initial finding of non-conformance, the sample underwent re-analysis at a referral laboratory, providing an additional layer of scrutiny. This secondary examination, however, corroborated the original result, confirming that the product did not meet the prescribed biotin requirements. This finding underscores the FSSAI's rigorous approach to ensuring the nutritional integrity of infant food products, emphasizing that compliance extends beyond marketing to the very composition of the formula.

These adjudication cases against Nestle India establish a significant precedent for the infant nutrition sector in India, highlighting the FSSAI's intensified focus on both marketing claims and product formulation. The regulatory actions bring renewed attention to how companies present ingredient-level claims, such as those related to human milk oligosaccharides (HMOs) and whey protein formulations, which have become common selling points in premium infant formulas globally. Regulators worldwide are increasingly cautious about such claims, driven by concerns that they might imply formula is comparable or superior to breastfeeding, a practice consistently prioritized by national nutrition policies for infants.

The enforcement of the Infant Milk Substitutes, Feeding Bottles and Infant Foods (Regulation of Production, Supply and Distribution) Act, 1992, alongside the 2020 Infant Nutrition Regulations, demonstrates a comprehensive regulatory framework aimed at safeguarding infant health. The 1992 law was specifically designed to curtail aggressive marketing by infant food manufacturers, and its continued application, in conjunction with modern food safety standards, reinforces the regulatory commitment to ethical promotion. Legal and compliance teams within the infant nutrition sector, particularly in India, must urgently review their product marketing claims and formulation compliance, as FSSAI is demonstrating heightened scrutiny and enforcement actions under the IMS Act and the 2020 Infant Nutrition Regulations, setting a precedent for similar regulatory challenges. The three cases will proceed independently before the adjudicating authority, and Nestle India has not yet issued a public statement regarding these developments.

Legal and compliance teams in the infant nutrition sector, particularly in India, must urgently review their product marketing claims and formulation compliance, as FSSAI is demonstrating heightened scrutiny and enforcement actions under the IMS Act and the 2020 Infant Nutrition Regulations, setting a precedent for similar regulatory challenges.

Source: Original reporting via industry news.